JP2019500894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500894A5 JP2019500894A5 JP2018543279A JP2018543279A JP2019500894A5 JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5 JP 2018543279 A JP2018543279 A JP 2018543279A JP 2018543279 A JP2018543279 A JP 2018543279A JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- variant
- seq
- domain
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021133074A JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251052P | 2015-11-04 | 2015-11-04 | |
| US62/251,052 | 2015-11-04 | ||
| PCT/US2016/060724 WO2017079694A2 (en) | 2015-11-04 | 2016-11-04 | Chimeric antigen receptors targeting her2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021133074A Division JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500894A JP2019500894A (ja) | 2019-01-17 |
| JP2019500894A5 true JP2019500894A5 (https=) | 2019-12-19 |
| JP6932709B2 JP6932709B2 (ja) | 2021-09-08 |
Family
ID=58662864
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543279A Expired - Fee Related JP6932709B2 (ja) | 2015-11-04 | 2016-11-04 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2021133074A Active JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2023065384A Withdrawn JP2023100653A (ja) | 2015-11-04 | 2023-04-13 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021133074A Active JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2023065384A Withdrawn JP2023100653A (ja) | 2015-11-04 | 2023-04-13 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11197919B2 (https=) |
| EP (2) | EP3371227B8 (https=) |
| JP (3) | JP6932709B2 (https=) |
| KR (1) | KR20180083874A (https=) |
| CN (2) | CN116063574A (https=) |
| AU (2) | AU2016349722A1 (https=) |
| BR (1) | BR112018009129A2 (https=) |
| CA (1) | CA3004306A1 (https=) |
| ES (1) | ES2909973T3 (https=) |
| IL (2) | IL259120B (https=) |
| MX (2) | MX2018005674A (https=) |
| RU (1) | RU2753695C2 (https=) |
| WO (1) | WO2017079694A2 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| KR20180083874A (ko) * | 2015-11-04 | 2018-07-23 | 사울 제이. 프라이스맨 | Her2를 표적화하는 키메라 항원 수용체 |
| IL287889B2 (en) | 2016-02-05 | 2024-03-01 | Hope City | Administration of engineered t cells for treatment of cancers in the central nervous system |
| US20200095547A1 (en) * | 2016-12-02 | 2020-03-26 | Darya ALIZADEH | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| CA3056591A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| KR102774451B1 (ko) * | 2017-11-14 | 2025-02-28 | 앱클론(주) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 |
| CN109608547B (zh) * | 2017-12-29 | 2022-03-15 | 郑州大学第一附属医院 | 表达Her2的嵌合抗原受体、慢病毒表达载体及其应用 |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3089167A1 (en) * | 2018-02-09 | 2019-08-15 | National University Of Singapore | Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy |
| EP3749685A4 (en) | 2018-02-09 | 2021-12-22 | National University of Singapore | ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY |
| WO2019157461A1 (en) | 2018-02-11 | 2019-08-15 | The Regents Of The University Of California | Car-t cells and autoimmune diseases |
| SG10201801219VA (en) | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| WO2019222579A1 (en) * | 2018-05-17 | 2019-11-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with myd88 and cd40 costimulatory domains |
| EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| US20230065784A1 (en) | 2019-03-21 | 2023-03-02 | City Of Hope | Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl |
| EP3966236A4 (en) * | 2019-05-07 | 2023-05-10 | The Board of Trustees of the Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| US20230072955A1 (en) * | 2020-01-23 | 2023-03-09 | Exuma Biotech Corp | Chimeric antigen receptors to her2 and methods of use thereof |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| EP4153635A4 (en) * | 2020-05-22 | 2024-06-26 | GC Cell Corporation | ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME |
| CN112481284B (zh) * | 2020-12-07 | 2023-07-25 | 深圳瑞吉生物科技有限公司 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
| WO2022187182A1 (en) * | 2021-03-02 | 2022-09-09 | The Trustees Of The University Of Pennsylvania | Targeting t regulatory cells to islet cells to stall or reverse type 1 diabetes |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CN117242090A (zh) | 2021-03-30 | 2023-12-15 | 希望之城公司 | CAR T细胞疗法和IFNγ |
| WO2023274385A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向her2的通用型car-t细胞及其制备方法 |
| EP4376859A4 (en) | 2021-07-29 | 2025-07-30 | Sonoma Biotherapeutics Inc | SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASES |
| CN117858943A (zh) * | 2021-08-24 | 2024-04-09 | 赛斯尔擎生物技术（上海）有限公司 | T细胞产品及其用途 |
| CN116023491A (zh) | 2021-10-25 | 2023-04-28 | 江苏众红生物工程创药研究院有限公司 | 抗cd26抗体及其应用 |
| WO2023172514A1 (en) * | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
| EP4490271A1 (en) | 2022-03-10 | 2025-01-15 | City of Hope | Membrane-bound il-12 for cellular immunotherapy |
| US20250228943A1 (en) | 2022-04-08 | 2025-07-17 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
| US20250222029A1 (en) * | 2022-04-08 | 2025-07-10 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| CN114805584B (zh) * | 2022-06-30 | 2022-09-09 | 上海优替济生生物医药有限公司 | 抗原结合蛋白及其用途 |
| AU2024264153A1 (en) | 2023-04-27 | 2025-11-13 | Vanudis GmbH | Coreceptor chimeric antigen receptor |
| WO2025101672A1 (en) | 2023-11-06 | 2025-05-15 | City Of Hope | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers |
| CN117924518B (zh) * | 2024-01-05 | 2025-08-22 | 苏州艾凯利元生物科技有限公司 | 用于nk细胞的嵌合抗原受体及工程化的nk细胞 |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
| WO2025217175A1 (en) * | 2024-04-08 | 2025-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Engineering immune cells to migrate to, infiltrate, persist, and expand in solid tumors |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1171468B1 (en) | 1999-04-09 | 2008-07-02 | Universität Zürich | Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment |
| DK1771482T3 (da) | 2004-07-22 | 2014-10-20 | Genentech Inc | HER2-antistofsammensætning |
| EP2158318A2 (en) * | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| JP2010536341A (ja) * | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| TR201904484T4 (tr) | 2009-11-03 | 2019-05-21 | Hope City | Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt). |
| US9586996B2 (en) * | 2010-04-30 | 2017-03-07 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| US8491908B2 (en) | 2010-06-01 | 2013-07-23 | Canon Kabushiki Kaisha | Composite particle, contrast agent for photoacoustic imaging, and method for producing the composite particle |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| DK3424953T3 (en) * | 2011-06-06 | 2020-11-02 | Novo Nordisk As | Terapeutiske antistoffer |
| BR122020002986A8 (pt) * | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| DK3456734T3 (da) | 2012-10-04 | 2022-04-19 | Res Found Dev | Serinproteasemolekyler og behandlinger |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| IL238323B2 (en) | 2012-10-30 | 2023-11-01 | Esperance Pharmaceuticals Inc | Antibody/drug conjugates and methods of use |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| WO2014182970A1 (en) * | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
| CN105940102B (zh) * | 2013-08-26 | 2020-02-18 | 海瑞克·亚柏坎 | 抗cd30嵌合抗原受体及其用途 |
| CN113307880B (zh) * | 2014-01-13 | 2025-07-04 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| CA2945388A1 (en) | 2014-04-23 | 2015-10-29 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
| KR20180083874A (ko) * | 2015-11-04 | 2018-07-23 | 사울 제이. 프라이스맨 | Her2를 표적화하는 키메라 항원 수용체 |
-
2016
- 2016-11-04 KR KR1020187015769A patent/KR20180083874A/ko not_active Ceased
- 2016-11-04 AU AU2016349722A patent/AU2016349722A1/en not_active Abandoned
- 2016-11-04 ES ES16863128T patent/ES2909973T3/es active Active
- 2016-11-04 JP JP2018543279A patent/JP6932709B2/ja not_active Expired - Fee Related
- 2016-11-04 EP EP16863128.1A patent/EP3371227B8/en active Active
- 2016-11-04 WO PCT/US2016/060724 patent/WO2017079694A2/en not_active Ceased
- 2016-11-04 EP EP22157943.6A patent/EP4074731A1/en not_active Withdrawn
- 2016-11-04 CA CA3004306A patent/CA3004306A1/en active Pending
- 2016-11-04 RU RU2018118817A patent/RU2753695C2/ru active
- 2016-11-04 CN CN202211409883.2A patent/CN116063574A/zh active Pending
- 2016-11-04 MX MX2018005674A patent/MX2018005674A/es unknown
- 2016-11-04 BR BR112018009129-4A patent/BR112018009129A2/pt not_active IP Right Cessation
- 2016-11-04 CN CN201680076412.0A patent/CN108779174B/zh not_active Expired - Fee Related
- 2016-11-04 US US15/773,754 patent/US11197919B2/en active Active
-
2018
- 2018-05-03 IL IL259120A patent/IL259120B/en unknown
- 2018-05-04 MX MX2022013498A patent/MX2022013498A/es unknown
-
2021
- 2021-08-18 JP JP2021133074A patent/JP7264954B2/ja active Active
- 2021-12-06 US US17/543,148 patent/US20220265796A1/en not_active Abandoned
-
2022
- 2022-01-10 AU AU2022200116A patent/AU2022200116A1/en not_active Abandoned
- 2022-04-13 IL IL292222A patent/IL292222A/en unknown
-
2023
- 2023-04-13 JP JP2023065384A patent/JP2023100653A/ja not_active Withdrawn
-
2024
- 2024-10-18 US US18/919,692 patent/US20250333471A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500894A5 (https=) | ||
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| IL292650A (en) | Chimeric antigen receptor T cells target il13ra2 | |
| TWI710572B (zh) | 改善配對的ｔ細胞受體 | |
| JP2017537627A5 (https=) | ||
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| ES2833162T3 (es) | Receptor de antígeno quimérico y su uso | |
| RU2685479C2 (ru) | Химерный антигенный рецептор | |
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| ES2959480T3 (es) | Acoplador de células T - antígeno trifuncional y métodos y usos del mismo | |
| ES2848478T3 (es) | Receptores quiméricos para antígenos y usos de estos | |
| JP2015518479A5 (https=) | ||
| JP2017500869A5 (https=) | ||
| JP2019528078A (ja) | 細胞治療のための構造的に活性なサイトカイン受容体 | |
| RU2016143384A (ru) | Трансгенные генетические метки и способы применения | |
| JP2016520074A5 (https=) | ||
| JP2018509163A5 (https=) | ||
| CN108779160A (zh) | 施用工程化t细胞以治疗中枢神经系统中的癌症 | |
| JP2016538855A5 (https=) | ||
| JP2017538401A5 (https=) | ||
| JP2019512251A5 (https=) | ||
| CN105802909B (zh) | 具有her2特异性tcr的t细胞制备物及其用途 | |
| Crowley et al. | Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH |